Safety, Efficacy of Weekly Versus 3-Weekly Docetaxel for MBC
Docetaxel, a taxane chemotherapeutic agent, is the mainstay of treatment for patients with metastatic breast cancer (MBC). Available evidence indicates that the frequency and extent of adverse events associated with docetaxel may be mediated by both the dose and length of treatment. This study helps pharmacists distinguish between the benefits and risks with weekly versus 3-weekly docetaxel. Read more.
|
PI3K Inhibitor-Induced Hyperglycemia: Avoid Insulin!
The phosphatidylinositol-3-kinase (PI3K) pathway is involved in numerous physiological functions, including cell growth, metabolism, survival, angiogenesis, and glucose metabolism. A recent review paper explored the etiology of hyperglycemia and provided pharmacists with detailed, practical advice recommendations on how to prevent and manage P13K inhibitor–associated hyperglycemia. Read more.
|